Synaptotagmins bind clathrin AP-2 with high affinity via their second C 2 domain, which indicates they are involved in coated pit function. We now report that expression of synaptotagmins lacking either the second C 2 domain or the entire cytoplasmic region potently inhibit endocytosis. Inhibition was dependent on two intramembrane cysteine residues that were found to be essential for synaptotagmin oligomerization. Cells expressing the wild-type, but not the mutant, truncated synaptotagmin fragment had a reduced number of clathrin-coated pits. These results suggest that the formation of synaptotagmin multimers is an important step in the regulation of coated pit assembly.
Receptor-mediated endocytosis utilizes clathrin-coated pits for efficient uptake of macromolecules from the extracellular space. A surface coated pit is constructed from two components, the clathrin triskelion and the AP-2 complex (1). The assembly of the pit occurs in a sequential fashion and appears to require the regulated binding of AP-2 to membranes (2) (3) (4) . When bound to plasma membranes, AP-2 facilitates the polymerization of clathrin triskelions into hexagonal lattices.
Binding of AP-2 to the inner membrane surface of fibroblasts has several characteristics (5, 6) . The binding site behaves like an integral membrane protein that can be removed by protease treatment. The released proteolytic fragment retains the ability to bind AP-2 and block AP-2 binding to isolated plasma membranes. Binding does not depend on calcium and occurs best at neutral pH (5) . AP-2 binding to the membrane is required but not sufficient for clathrin polymerization (6) . Proteins with the characteristics of an AP-2-binding site are the synaptotagmins (7) .
Synaptotagmins are type I transmembrane proteins. There are at least 12 different genes in mammals (8 -10) . The best studied member of this family is synaptotagmin I (Syt I). 1 The cytoplasmic portion of the molecule contains two C 2 domains (11) . Both domains bind Ca 2ϩ . The first C 2 domain (C 2 A) of synaptotagmin binds phospholipids in a Ca 2ϩ -dependent manner. This domain also interacts with syntaxin (8, 12) . By contrast, the second C 2 domain (C 2 B) contains the high affinity, Ca 2ϩ -independent binding site for AP-2. C 2 B also binds polyinositolphosphates (13) , , SV2A (15) , the "synprint region" of N-and P/Q-type Ca 2ϩ channels (16, 17) and undergoes a Ca 2ϩ -dependent interaction with itself (18, 19) . Genetic and biochemical evidence suggests synaptotagmin has important functions in both exocytosis and endocytosis. Mice deficient in synaptotagmin I are defective in Ca 2ϩ dependent, fast synchronous release of neurotransmitters (20) , which suggests that synaptotagmin I plays a role in the exocytosis of synaptic vesicles. Microinjected synprint peptides block synaptic transmission (21, 22) while microinjected anti-C 2 A IgG causes synaptic vesicles to accumulate at terminals (23) . On the other hand, functional disruption of the synaptotagmin gene in Caenorhabditis elegans causes a marked depletion of synaptic vesicles, which suggests it is involved in endocytosis (24) . Drosophila lacking synaptotagmin, by contrast, do not exhibit the same dramatic reduction in synaptic vesicle number (25) . The microinjection of anti-C 2 B polyclonal IgG into squid axons depletes synaptic vesicles at nerve terminals (26) . Biochemical experiments also suggest that the tyrosine-based sequence YXX⌽, which targets receptors to coated pits, enhances AP-2 interaction with synaptotagmin C 2 B domains (27) . A synergistic interaction between AP-2, synaptotagmin, and receptors containing YXX⌽ motifs could explain why coated pits are dramatically increased in cells overexpressing transferrin receptors (28, 29) .
Although AP-2 binds to all synaptotagmins tested so far (7, 8, 30) , there is no direct evidence that the molecule is involved in coated pit function. The phenotype of the C. elegans synaptotagmin mutants and the loss of synaptic vesicles following antibody injection into squid axons could be indirect effects. We have now tested directly if synaptotagmins participate in endocytosis by searching for forms of the molecule that act as dominant negative inhibitors of endocytosis. Our results show that expression of synaptotagmin lacking the C 2 B domain markedly inhibits receptor-mediated endocytosis and, in parallel, reduces the number of cell surface-coated pits. This effect is totally independent of the precise sequence of the transmembrane region of the synaptotagmin fragment, but depends on two conserved cysteine residues. These results suggest synaptotagmin plays a direct role in coated pit function.
EXPERIMENTAL PROCEDURES
Materials-Dithiothreitol, phenylmethylsulfonyl fluoride, and paraformaldehyde were obtained from Fluka (Ronkonkoma, NY). Horseradish peroxidase-labeled goat anti-mouse IgG was from Cappel (West Chester, PA). Myc mAb was from Santa Cruz Biotechnology (Santa Cruz, CA), while Myc pAb was from Upstate Biotechnology (Lake Placid, NY). A FLAG mAb was from Sigma. Rabbit anti-mouse IgG conjugated to fluorescein isothiocyanate, goat anti-rabbit IgG conjugated to TRITC, goat anti-mouse IgG, donkey anti-sheep IgG conjugated to 15-nm gold, rabbit anti-goat IgG conjugated to 10-nm gold all were from Zymed Laboratories Inc. (South San Francisco, CA). Sheep anti-mouse IgG was from Cappel Inc. (Westchester, PA). PMCA (3-pyrenemethyl-23,24-dinor-5-cholen-22-oate-3␤-yl oleate), DiI (1,1Ј-dioctyadecyl-3,3,3Ј,3Ј-tetramethyl-indocarbocyanine perchlorate), and transferrin conjugated to TRITC were from Molecular Probes, Inc. (Eugene, OR). Protein G-Sepharose 4 fast flow and protein A-Sepharose CL-4B were from Amersham Pharmacia Biotech (Ronkonkoma, NY).
Construction of Vectors-A pair of complementary oligonucleotides corresponding to the 9E10 Myc epitope (31) (AATTGCCATGGAGCAG-AAGCTGATCAGCGAGG AGGACCTGAACGG and AATTCCGTTCAG-GTCCTCCTCGCTGATCAGCTTCTGCTCCATGGC) were annealed and inserted into EcoRI restriction site (position 910) of pCMV 5 (32), creating a new expression vector designated pCMVmyc. This vector contains sequences encoding the Myc epitope (MEQKLISEEDLN), preceded by a Kozak sequence and followed by a polycloning site. A pair of complementary oligonucleotides corresponding to the FLAG epitope (AATTGCCATGGACTACAAGGACGATGACGATAAGGG and AATTC-CCTTATCGTCATCGTCCTTGTAGTCCATGGC) were annealed and inserted into the EcoRI restriction site (position 910) of pCMV5 (32) , creating a new expression vector designated pCMVFLAG. This vector contains sequences encoding the FLAG epitope (MDYKDDDDK) preceded by a Kozak sequence and followed by a polycloning site. A tetracycline inducible mammalian expression vector pUHDmyc was constructed by replacing SalI (blunted)/BamHI fragment of pUHD 10-3 (33, 34) with a SacI (blunted)/BamHI of pCMVmyc. The ponasterone A inducible mammalian expression vector pINDmyc was constructed by annealing a pair of complementary oligonucleotides corresponding to the 9E10 Myc epitope (31) (AATTGCCATGGAGCAGAAGCTGATCAG-CGAGGAGGACCTGAACGG and AATTCCGTTCAGGTCCTCCTCGC-TGATCAGCTTCTGCTCCATGGC) and inserting the duplex into the EcoRI restriction site of pIND (Invitrogen: Ecdysone-Inducible Expression Kit). This vector contains sequences encoding the Myc epitope (MEQKLISEEDLN), preceded by a Kozak sequence and followed by a polycloning site.
Recombinant Proteins-Plasmids encoding polypeptides of different regions from synaptotagmin I and VII fused with Myc were constructed by polymerase chain reaction amplification of the corresponding cDNA sequences using oligonucleotides containing flanking restriction sites and pfu DNA polymerase (Stratagene, La Jolla, CA). The resulting polymerase chain reaction fragments were then cloned into the mammalian expression vectors pCMVmyc or pUHDmyc. Oligonucleotide primers used for polymerase chain reactions to generate the listed expression vectors were: pUHDmyc Syt Iwt (residues 1-421), oligonucleotides JZ21 (CGCGAATTCAGGTGAGTGCCAGTCATCCTGA) and JZ32 (GCAGATCTACTTC TTGACAGCCAGCATGGC); pUHDmyc Syt I⌬C 2 B (residues 1-267), oligonucleotides JZ21 and JZ31 (GCAGATCT-ATTCTTTCTCAGCGCTCTGGAG); pCMVmyc Syt VIIwt (residues 1-403 (8), JZ26 (CGCGAATTCAGTACCGGGACCCGGAGGCGGC) and JZ36 (GCTCTAGATCAGGCTTTCAGCTGGTGCCACTG); pCMVmyc Syt VII⌬C 2 B (residues 1-263), oligonucleotides JZ26 and JZ35 (GCTCTAGATCACCCATCGCTGCATGGCTTCAG); pCMVmyc Syt VII⌬C 2 AB (residues 1-133), oligonucleotides JZ26 and JZ44 (GCT-CTAGACTATCGGCTGC AGCCCTC); pCMVmyc Syt VII⌬Cyt (residues 1-49), oligonucleotides JZ26 and JZ46 (GCTCTAGACTAGTAGCGTT-TGCCCAG); pCMVmyc Syt VII⌬Cyt* (residues 1-49), oligonucleotides JZ26 and JZ54 (GCTCTAGACTAGTAGCGTTTGCCCAGTTTGCGCT-GAGCCCAGTGGGCCAGG); pCMVmyc Syt VII⌬CytC38A (residues 1-49), oligonucleotides JZ26 and JZ56 (GCTCTAGACTAGTAGCGTT-TGCCCAGTTTGCGCTGACACCAGTGGGCCAGGC); pCMVmyc Syt VII⌬CytC41A (residues 1-49), oligonucleotides JZ26 and JZ57 (GCTC-TAGACTAGTAGCGTTTGCCCAGTTTGCGCTGAGCCCAGTG).
Polymerase chain reaction fragments were digested with EcoRI-BglII (JZ21-JZ32, JZ21-JZ32), and they were cloned into the same sites of pUHDmyc; or with EcoRI-XbaI (JZ26-JZ36, JZ26-JZ35, JZ26-JZ44, JZ26-JZ46, JZ26-JZ54, JZ26-JZ56, and JZ26-JZ57) and then cloned into the same sites of pCMVmyc. The junction sites of all plasmids were confirmed by nucleotide sequencing using the Sequenase TM Version 2.0 DNA sequencing kit according to the manufacturer's instruction (U. S. Biochemical Corp., Cleveland, OH). Other plasmids encoding polypeptides of synaptotagmin VII and synaptotagmin I fused with FLAG or Myc were constructed by replacing the ERI/XbaI fragment of pCMV-FLAG and pINDmyc with the ERI/XbaI fragments encoding the respective synaptotagmin-peptides from pCMVmyc Syt VII⌬Cyt (residues 1-49), pCMVmyc Syt VII⌬Cyt* (residues1-49 C38A, C41A), and pCMVmyc Syt I⌬Cyt (residues 1-86) or by replacing the EcoRI/BglII fragment of pCMV FLAG with the EcoRI/BglII fragments of pCMVmyc Syt VII⌬C2B (residues 1-262) and pCMVmyc Syt I⌬C2B (residues1-268).
Cell Culture-The (35) . pUHD 65-18, which contains the cDNA encoding wt Syt VII under control of the tTA-responsive promoter, was constructed by inserting the EcoRI/XbaI fragment from pCMV 65-18a into the same sites of pUHD 10-3 (33) . The plasmid (10 g) was introduced into tTA HeLa cells by calcium phosphate transfection, along with the plasmid pBSpac (0.5 g) containing a puromycin resistance gene (36) . Positive clones resistant to puromycin were selected and cultured in DMEM containing 200 ng/ml puromycin, 400 g/ml G418, and 2 g/ml tetracycline. Puromycin-resistant clones were screened by Western blot for expression of Syt VII using a polyclonal anti-Syt VII IgG (8) 60 h after removing tetracycline from the medium. Stable transfected EcR-293 cell lines containing the ponasterone A-inducible synaptotagmin VII mutants were made using a kit (Invitrogen): pINDmyc syt VII⌬Cyt-(1-49) and pINDmyc syt VII⌬Cyt*-(1-49, C38A, C41A) under the control of five hybrid ecdysone response elements and the minimal heat shock promoter were constructed by inserting the EcoRI/XbaI fragments from pCMVmyc Syt VII⌬Cyt and pCMVmyc syt VII⌬Cyt* into the same sites of pINDmyc. The plasmids (30 g) were introduced into EcR-293 cells by calcium phosphate transfection according to the manufacturer's instructions. Positive clones resistant to Zeocin (Invitrogen) were selected by limited dilution and cultured in DMEM supplemented with 10% fetal bovine serum, 400 g/ml Zeocin, 600 g/ml G418, and 100 units/ml each of penicillin and streptomycin (medium B). Zeocin-resistant clones were screened by Western blot for expression.
Preparation of PMCA and DiI-labeled LDL-PMCA LDL was prepared as described previously (37) . To prepare DiI LDL, a 150-l sample of DiI (3 mg/ml) dissolved in Me 2 SO was added with gentle vortex mixing to 6 ml of human lipoprotein-deficient serum containing 3.5 mg of human LDL. The mixture was incubated for 24 h at 37°C before adding 0.5 g of KBr and loading the sample in two, 3-ml quick seal tubes (Beckman Instruments, Inc., Palo Alto, CA). The tubes were filled with 1.063 mg/ml KBr and centrifuged at 100,000 rpm in a TLA 100.3 rotor (Beckman Instruments, Inc., Palo Alto, CA) for 5 h at 4°C. The top floating LDL band was extracted by tube slicing and dialyzed overnight at 4°C in the dark against buffer consisting of 50 mM Tris, pH 7.4, 150 mM NaCl, and 0.3 mM EDTA.
Fluorescent LDL Uptake Assay-tTA HeLa cells attached to coverslips were transfected with plasmids containing wt or mutant synaptotagmin using the calcium phosphate method (38) . Twenty-four hours after transfection, cells were switched to DMEM supplemented with 10% (v/v) human lipoprotein-deficient serum to induce LDL receptors. Thirty-six to thirty-eight hours later, which was 60 -62 h post-transfection, cells were incubated with 25 g/ml fluorescent labeled LDL (either PMCA labeled or DiI labeled) at 37°C for 15 min. The coverslips were washed twice with ice-cold PBS at 4°C. After fixing with 3% paraformaldehyde, transfected cells were identified by indirect immunofluorescence staining with Myc mAb. Transfected cells were then scored for fluorescent LDL uptake.
125
I-LDL Uptake Assay-EcR-293 cells stably transfected with the indicated cDNA were either induced on not induced with ponasterone A for 48 h. The cells were then assayed for the binding and uptake of 125 I-LDL as described previously (39) . Immunofluorescence-Immunofluorescence was carried out on either non-permeabilized or permeabilized cells using standard methods (40) . Cells grown on coverslips were fixed for 30 min at 4°C with 3% paraformaldehyde in 20 mM Hepes-NaOH buffer, pH 6.8, containing 100 mM KCl, 5 mM MgCl 2 , 3 mM EGTA. The coverslips were washed and incubated with the indicated antibodies for 1 h at 4°C. Coverslips were washed again and mounted on glass slides with a drop of SlowFade TM (Molecular Probes, Inc., Eugene, OR) according to the manufacturer's instruction.
Immunogold Localization-Cells were subjected to the indicated treatment, washed with ice-cold PBS at 4°C, and fixed with 3% paraformaldehyde in PBS, pH 7.6. Immunogold localization of receptors and Myc-tagged proteins was carried out as described previously (41) . Briefly, cells were incubated for 60 min in the presence of the indicated antibody (either Myc mAb, 30 g/ml alone, or Myc mAb plus polyclonal anti-LDL receptor IgG, 50 g/ml together) at 4°C. Cells were washed and incubated further in the presence of either goat anti-mouse IgG (50 g/ml) or a mixture of sheep anti-mouse IgG and goat anti-rabbit IgG (50 g/ml). Finally, cells were washed again and incubated in the presence of either rabbit anti-goat IgG conjugated to 10-nm gold (1:30 dilution) or a mixture of donkey anti-sheep IgG conjugated to 15-nm gold and rabbit anti-goat IgG conjugated to 10-nm gold (1:30 dilution for each). All the antibodies were diluted in PBS containing 0.15% bovine serum albumin, pH 7.6. All washes were three times for 30 min in PBS containing 0.15% bovine serum albumin. After the final wash, cells were fixed with 2% glutaraldehyde in PBS for 30 min, followed by 1% OsO 4 in PBS for 60 min. The cells were embedded in Epon, sectioned, and examined with a JOEL 100 CX electron microscope. Quantification of coated pits and number of gold particles was determined from a random set of electron micrographs taken by a blind observer as described previously (42) .
Oligomerization Assay-Monolayers of human embryonic kidney 293 cells were set up on day 0 (7.5 ϫ 10 5 cells/60-mm dish) and cultured in medium A in 5.5% CO 2 at 37°C. On day 1 cells were co-transfected with the indicated plasmids using a calcium phosphate transfection kit (Stratagene). PVA1, which encodes the adenovirus-associated I (VAI) RNA gene that enhances translation of mRNA produced by transfected cDNA (43) , was included in all transfections at 2 g/dish. DMEM supplemented with 6% modified bovine serum was used as transfection medium. Three hours after transfection the cells were switched again to medium A. After incubation for 18 -20 h, the cells were washed twice with PBS on ice, harvested, and solubilized for 1 h in 300 l of TETN 100 (30 mM Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5% Triton X-100 and protease inhibitors) per 60-mm dish. The detergent-solubilized cell extracts were incubated with either Myc pAb (15-20 g/extract of 60-mm dish) or M5 FLAG mAb (15 g/extract of 60-mm dish) overnight. The next day, protein A or G coupled to Sepharose was preblocked in TETN 100, added to the mixture, and further incubated for 3 h. The Sepharose beads were washed 2 times 5 min in TETN 100* (TETN 100 minus protease inhibitors), 2 times 5 min in TETN 250 (30 mM Tris, pH 7.5, 250 mM NaCl, 1 mM EDTA, 0.5% Triton X-100), and once again 2 times 5 min in TETN100*. The pellet (each lane contains immunoprecipitate from 1 dish of cells) was separated by SDS-PAGE and immunoblotted with Myc pAb and M5 FLAG mAb.
Miscellaneous Procedures-SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out as described by Ref. 44 and the gels were calibrated with prestained SDS-PAGE standards (Bio-Rad). Immunoblotting was performed according to manufacturer's instruction in the ECL TM immunoblotting kit (Amersham Pharmacia Biotech).
RESULTS

Expression of Synaptotagmin Lacking C 2 B Blocks
Endocytosis-A transient expression assay was used to determine if either wild-type synaptotagmin or truncated forms of synaptotagmin affected the endocytosis of fluorescent LDL in tTA HeLa cells. The expression of the C 2 B domain in these cells resulted in the formation of an insoluble cytoplasmic material, making it impossible to assess directly the function of this domain using this type of assay. We then studied the effects of expressing the full-length synaptotagmin I or a truncated synaptotagmin I lacking the C 2 B domain (Syt I⌬C 2 B). All expressed proteins were tagged on the extracellular N terminus with a Myc epitope for easy detection of expressing cells by immunofluorescence. Approximately 60 h after transfection, cells that had been cultured for 36 h without lipoproteins were incubated in the presence of fluorescent PMCA LDL for 15 min at 37°C. They were then fixed and stained with a Myc mAb. Cells expressing full-length synaptotagmin I internalized PMCA LDL as efficiently as non-transfected cells (compare Fig.  1, a and b) . By contrast, internalization of PMCA LDL was markedly reduced in cells expressing synaptotagmin I lacking the C 2 B domain (compare c and d). We quantified these observations by classifying the cells expressing full-length or truncated synaptotagmin I into three categories; no uptake, reduced uptake, or normal uptake of PMCA LDL relative to nearby untransfected control cells. These quantifications showed that nearly 85% of the cells expressing synaptotagmin I showed normal uptake compared with 20% of cells expressing the synaptotagmin I fragment that lacks the C 2 B domain. Uptake was completely inhibited in 70% of Syt I⌬C 2 B cells and partially inhibited in another 10%. Therefore, expression of synaptotagmin I lacking the C 2 B domain inhibits receptormediated endocytosis of LDL.
Multiple synaptotagmins are expressed in brain. Synaptotagmin I can only be detected in neuronal and endocrine cells (9) whereas other synaptotagmins, such as synaptotagmin VII, are also present at low levels outside the brain (8) . Since all synaptotagmins tested bind to AP-2, a similar function in endocytosis would be expected. To test this, we designed five different cDNAs for synaptotagmin VII (Fig. 2) : full-length synaptotagmin VII (Syt VIIwt), synaptotagmin VII lacking the C 2 B domain (Syt VII⌬C 2 B), synaptotagmin VII lacking both 
the C 2 A and C 2 B domains (Syt VII⌬C 2 AB), and synaptotagmin VII lacking the entire cytoplasmic portion of the molecule (Syt VII⌬Cyt). Similar to synaptotagmin I, expression of synaptotagmin VII lacking the C 2 B domain in tTA HeLa cells blocked uptake of DiI LDL while wild-type synaptotagmin had no effect (data not shown). Furthermore, synaptotagmin VII fragments lacking both C 2 A and C 2 B domains or the entire cytoplasmic tail also potently inhibited DiI LDL uptake (Fig. 3, a and b) . The synaptotagmin VII fragment lacking the cytoplasmic part is only 50 residues long, consisting of just a transmembrane region preceded by a short extracellular segment. Nevertheless, the inhibitory effect of the fragment on endocytosis could be confirmed in all cell types we tested (HeLa, neuro-2A, COS-7, and NIH3T3), indicating a general effect on endocytosis.
The N-terminal Synaptotagmin VII Fragment Acts as a Dominant Negative-The unexpected phenotype of cells expressing the truncated synaptotagmins could be due to an inactivation of endogenous synaptotagmin. If this is the case, then increasing the wild-type synaptotagmin level in the cell should overcome the inhibitory effects of the truncated molecule. Therefore, we established a stable tTA HeLa cell line expressing wild-type synaptotagmin VII under the control of an inducible promoter (designated UHD65-18 cells). We then used the transient transfection assay to see whether synaptotagmin VII lacking the cytoplasmic region (Syt VII⌬Cyt) could inhibit DiI LDL uptake in these cells (Fig. 3, c and d) . LDL internalization after induction of synaptotagmin VII expression in UHD65-18 cells was unchanged (data not shown). Introduction of the truncated fragment into the induced cells had no effect on LDL uptake (arrows, c and d). Quantitative analysis of DiI LDL uptake (Table I) showed that ϳ77% of the induced UHD65-18 cells expressing synaptotagmin VII lacking the cytoplasmic region internalized normal amounts of the DiI LDL. By contrast, only 29% of the parental tTA HeLa cells expressing Syt VII⌬Cyt took up DiI LDL. Two independent clones of UHD65-18 cells gave similar results.
Previous studies have shown that synaptotagmin I is palmitoylated near the transmembrane region and that all synaptotagmins contain cysteine residues at equivalent positions (8, 45) . In synaptotagmin VII these cysteine residues are at positions 38 and 41 and could potentially be involved in the inhibitory effects of the expressed fragment. To test this, we mutated these two residues in the truncated synaptotagmin fragment (Syt VII⌬Cyt*, Fig. 2 ) and expressed the fragment in tTA HeLa cells. A side-by-side comparison of the effects of the wild-type and mutant synaptotagmin fragments (Fig. 3 , e and f) revealed that substitution of these cysteine residues abolished the ability of truncated synaptotagmin VII to inhibit DiI LDL uptake. Nearly 86% of these cells took up DiI LDL at normal levels. Changing the Cys 38 and Cys 41 to alanine individually generated a molecule that was not as potent as the double mutant at inhibiting DiI LDL uptake (data not shown).
These results suggest that the inhibitory effects of truncated synaptotagmin VII could depend on the formation of heterooligomers with endogenous synaptotagmin. We could not detect endogenous synaptotagmin VII with the available antibodies. Therefore, to see whether we could detect synaptotagmin oligomer formation, we co-expressed Myc-tagged truncated synaptotagmin VII (Myc-Syt VII⌬Cyt) and FLAG-tagged synaptotagmin VII lacking the C 2 B domain (FLAG-Syt VII⌬C 2 B) in 293 cells, immunoprecipitated with FLAG-pAb and analyzed the pellet (lanes 1-4) and the supernatant (lanes 5-8) fractions for the presence of Myc-and FLAG-tagged proteins by immunoblotting (Fig. 4a) . FLAG pAb immunoprecipitates contained virtually all the expressed protein (FLAG, compare lanes 2-4 with 6 -8) while no tagged protein was present in immunoprecipitates prepared from non-transfected cells (lane 1). FLAG pAb immunoprecipitates from cells co-expressing FLAG-Syt VII⌬C 2 B and Myc-Syt VII⌬Cyt contained approximately equal amounts of the two proteins (Myc, lane 2) . The intensity of the Myc-positive band in the FLAG immunoprecipitates was markedly less when the cells were co-expressing FLAG-Syt VII⌬C 2 B with Myc-Syt VII⌬Cyt* (lane 3). Myc-tagged protein was detected in all of the supernatant fractions (lanes 5-7) , indicating that the Myc-tagged protein was in excess over FLAG-tagged protein in these cells. We did not see a Myc-positive band in FLAG immunoprecipitates from cells that were not expressing any Myc-tagged proteins (lanes 4 and 8) . Identical results were obtained when a FLAG-tagged synaptotagmin I fragment was substituted for the FLAG-tagged synaptotagmin VII fragment (Fig. 4b) or when the FLAG and Myc epitopes used to tag the proteins were exchanged (data not shown). Therefore, truncated synaptotagmin VII specifically forms hetero-oligomers with the longer synaptotagmin only when the two cysteine residues in the transmembrane region are present.
We used EcR-293 cells stably expressing each fragment under the control of an ecdysone inducible promoter to further explore the effects of truncated synaptotagmin VII fragments on endocytosis. Ponasterone A induced expression of the same amount of both the wild-type and mutant fragments (Fig. 5a,  compare lanes 1, 3 with 2, 4) . PMCA LDL uptake was used to FIG. 2 . A map of full-length synaptotagmin VII and the modified forms of the protein used in this study. All expressed proteins contained a Myc tag at the N terminus, which is exposed to the extracellular space. This was achieved by cloning truncated and mutated Syt VII into a pCMVmyc vector as described. Syt VII⌬C 2 B contains amino acid residues 1-263; Syt VII⌬C 2 AB contains 1-133; Syt VII⌬Cyt contains 1-49; Syt VII⌬Cyt* contains 1-49 with Cys 38 and Cys 41 mutated to Ala residues. A and B denote the two C 2 domains; TMD, transmembrane domain; Myc, Myc epitope; **, position of the two cysteine residues that were changed to alanine.
assess the overall behavior of these cells after growth in the presence of 10 M ponasterone A for 48 h (Table II) . In two different trials, we found that ϳ71% of the cells expressing full-length synaptotagmin VII took up LDL while only ϳ35% of the cells transfected with truncated synaptotagmin VII fragment internalized the molecule. The mutant truncated synaptotagmin VII fragment did not inhibit.
We next measured the effect of these fragments on the uptake of 125 I-LDL into EcR-293 cells (Fig. 5) . Cells stably transfected with either wild-type or mutant-truncated synaptotagmin VII fragments were grown for 48 h in the presence or absence of ponasterone A to regulate fragment expression. For the last 24 h of this incubation, they were grown in lipoproteindeficient serum. The cells were then incubated in the presence of 125 I-LDL for 1 h. Uninduced EcR-293 cells transfected with truncated synaptotagmin VII internalized ϳ175 ng/mg protein (Fig. 5b) . Induction of fragment expression, however, reduced uptake by ϳ55%. The expression of the mutant-truncated synaptotagmin VII fragment had no effect on LDL uptake. Expression of these constructs had little effect on the binding of 125 I-LDL to EcR-293 cells (c). The time course of 125 I-LDL uptake in induced (E) and uninduced (Ⅺ) EcR-293 cells transfected with truncated synaptotagmin VII was also compared (d). The induced cells internalized 125 I-LDL more slowly than uninduced cells and the total amount internalized after 90 min was reduced Ͼ60%. Together, these results demonstrate that the truncated synaptotagmin VII fragment inhibits endocytosis only when the transmembrane region contains wild-type cysteine residues.
Synaptotagmin Fragments Reduce Coated Pits-Punctate immunofluorescence staining of transiently transfected cells suggested that clusters of both LDL receptors and Myc-tagged Syt were in coated pits (data not shown). We used immunogold to co-localize LDL receptors and the Myc tag (Fig. 6, a and b) . After transiently expressing either full-length (Fig. 6a) or truncated synaptotagmin VII (Fig. 6b) , cells labeled with mAb Myc gold (large arrows, 15 nm gold) and pAb LDL receptor gold (small arrows, 10 nm gold) could be detected. In both sets of cells, LDL receptor gold was found clustered in clathrin-coated pits, and these same pits often contained the Myc-tagged synaptotagmin. The ability of LDL receptors to cluster in coated pits, therefore, does not seem to be impaired in cells expressing truncated synaptotagmin VII. Furthermore, single labeling with mAb Myc immunogold (Fig. 6c) showed that ϳ70% of the coated pits we found in cells expressing full-length synaptotagmin VII were labeled, with each labeled pit containing 5-6 gold particles. The short synaptotagmin VII fragment that lacks the entire cytoplasmic sequence was also found in coated pits (Fig. 6d) .
We noticed that the cells transiently transfected with trun-
TABLE I Quantitative analysis of cells that internalized DiI LDL
Cells were transfected with the indicated plasmid and allowed to internalize DiI LDL for 15 min at 37°C (see Fig. 3 ). Anti-Myc IgG positive cells were scored for the presence or absence of DiI LDL. cated synaptotagmin VII had fewer coated pits. Quantitative analysis showed that these cells had ϳ37% fewer pits compared with cells expressing the full-length synaptotagmin VII. The cysteine to alanine mutant form of the truncated synaptotagmin VII had normal numbers of coated pits (Table III) . The same result was obtained in a second independent experiment (data not shown). These results prompted us to evaluate the number of coated pits in EcR-293 cells expressing truncated synaptotagmin VII. The number of coated pits per unit length of plasma membrane in ponasterone A-induced cells was reduced ϳ44% relative to uninduced cells. Therefore, in two different experimental protocols, truncated synaptotagmin VII appeared to reduce the number of coated pits.
DISCUSSION
Several studies indicate that membranes in the endocytic pathway contain a regulated binding site for AP-2 (2-4). AP-2 binding to membranes is strongly correlated with the formation of clathrin lattices (2) (3) (4) . Therefore, these binding sites must be the cornerstone of coated pit assembly and function. A program of study focused on identifying these binding site(s) (5, 6, 46, 47) culminated in the discovery that synaptotagmin I bound AP-2 with high affinity in vitro (7). Subsequently we found that AP-2 binding to the C 2 B domain occurs for all the synaptotagmins we tested (8, 30) . The results of the current study provides evidence that multimerization of synaptotagmin is linked to endocytosis by coated pits.
Synaptotagmins lacking the C 2 B domain, either alone or in combination with other parts of the cytoplasmic region, behaved like dominant-negative inhibitors of LDL uptake. This result was obtained with both synaptotagmin I and VII. A fragment consisting of as little as the short N-terminal sequence and transmembrane region of synaptotagmin VII was a potent inhibitor of endocytosis. The expression of these fragments also blocked fluorescent transferrin internalization (data not show), which suggests they have a general effect on endocytosis by coated pits. Currently there are only four known ways to inhibit receptor-mediated endocytosis: remove receptors from the cell surface (48); prevent receptor clustering in coated pits (49) ; arrest membrane fission during coated pit budding (35, 50, 51) ; or block coated pit internalization (52) (53) (54) . Our data characterize a fifth mechanism to inhibit endocytosis, namely overexpression of the N-terminal sequence of synaptotagmin.
The reduction in coated pits seen in cells expressing the short N-terminal fragment of synaptotagmin VII suggests that the primary defect is clathrin lattice assembly. The reduced number of coated pits in cells permanently transfected with this synaptotagmin fragment (56% of normal) correlated with the inhibition of LDL uptake (ϳ40% of normal) in these cells. Presumably we did not see 100% inhibition because not every cell expressed inhibitory levels of the synaptotagmin fragment. In transient transfection assays, cells expressing this fragment had clustered receptors in the remaining coated pits (Fig. 6) . We do not know, however, if the cells with clustered receptors expressed enough of the truncated protein to inhibit LDL uptake. Thus, we cannot rule out the possibility that, in addition to inhibiting coated pit assembly, the short synaptotagmin VII fragment causes the assembly of pits that look normal but are unable to complete the internalization process.
We identified two requirements for the inhibitory activity of truncated synaptotagmin: the absence of the C 2 B domain and the cysteine residues at positions 38 and 41. Expression of wild-type molecules had no effect on endocytosis, nor did the transmembrane domain of the mutant fragment, so inhibition cannot be attributed to the nonspecific effects of overexpressing a transmembrane domain. Synaptotagmin I and synaptotagmin VII have very different extracellular domains so this region of the molecule most likely is not involved either. This leaves an interaction between the transmembrane domain of truncated synaptotagmin and some other molecule(s) in the cell. There might be an unknown molecule required for coated pit internalization that is inactivated by truncated synaptotagmin. Alternatively, the truncated synaptotagmin oligomerizes with endogenous synaptotagmins and prevents their function. We favor the second possibility because synaptotagmins are known to form homomultimers. Previous studies showed that sequences N-terminal to the two C 2 domains of synaptotagmin I mediate self-association of synaptotagmin I into large homomultimers in a calcium-independent manner (55, 56) . In addition, the C 2 B domains of synaptotagmin I and II bind to synaptotagmins in a calcium-dependent manner, resulting in calcium-dependent homomultimerization (18, 19, 57) . We found in co-transfection assays that the synaptotagmin VII fragment lacking the entire cytoplasmic sequence formed stable oligomers with itself and with longer fragments (Fig. 4) . Oligomerization was markedly reduced when the cysteine residues in the transmembrane region were replaced with alanine residues (Fig. 4) . Furthermore, overexpression of full-length synaptotagmin blocked the inhibition of endocytosis by truncated synaptotagmin VII fragments, suggesting it was seques- tering the truncated molecule and preventing its action (Fig. 5) . These data suggest that synaptotagmin has a natural tendency to self-associate via interactions involving the transmembrane region, and that these interactions require the two cysteine residues in the transmembrane region.
The ability of truncated synaptotagmin VII to reduce the number of coated pits and block LDL uptake suggests synaptotagmin has a direct role in clathrin-coated pit assembly (7) . The precise molecular interactions required for coated pit assembly have not been determined. Most likely assembly is dependent on a complex set of interactions between AP-2, clathrin, the cytoplasmic portion of transmembrane proteins that cluster in coated pits and membrane lipids (58) . AP-2 (7) and inositol polyphosphates are two key molecules involved in coated pit function that interact with the synaptotagmin C 2 B domain. Inositol polyphosphates are well known for their ability to modulate interactions between AP-2 and clathrin (59) and enhance the recognition of YXX⌽ sorting signals by AP-2 and AP-1 (60). They could also modulate AP-2 binding to synaptotagmins. Therefore, the C 2 B domain of synaptotagmin appears to be in a critical position to influence several aspects of coated pit assembly and function. The presence of the truncated synaptotagmin in the cell would cause the formation of oligomeric complexes that lack the C 2 B domain, thereby depleting the complex of binding sites for structural and regulatory molecules critical for coated pit assembly. These conditions might also lead to the assembly of defective pits.
Neurons express very high levels of the various synaptotagmins whereas other cells, such as fibroblasts or hepatocytes, appear to have very low levels of these proteins. The relationship between expression level and the role these proteins play in endocytosis is unclear. It is possible that the observed levels of synaptotagmins in non-neuronal cells is sufficient to support coated pit assembly. We also cannot rule out the possibility that an additional, yet to be identified, synaptotagmin ex- (lanes 1 and 2) , Myc-Syt VII⌬Cyt* (lanes 3 and 4) or vector alone (lanes 5 and 6) were grown in the presence (lanes 1, 3, and 5 pressed in these cells is the critical molecule for coated pit assembly. Alternatively, synaptotagmins may play a regulatory role in coated pit assembly and are only required at high levels in cells like neurons where fast, high throughput synaptic vesicle traffic demands a more rapid and efficient endocytic machinery. Multiple proteins are now known to be involved in coated pit budding, suggesting that the anchoring of the clathrin to the membrane and its subsequent action during invagination is a complex process. of Syt Cells were prepared as described in Fig. 6 and processed for electron microscopy. Pictures were taken of cells positive for anti-Myc IgG gold and evaluated for the number of coated pits and number of pits labeled with anti-Myc IgG gold. 
